Evaluation of Prophylaxis with Norfloxacin and Ceftriaxone versus Ciprofloxacin during the Period of Neutropenia after Haematopoietic Stem Cell Transplantation: Retrospective Analysis of Two Sequencial Cohorts


Background: The aim of this study was to evaluate the occurrence of febrile neutropenia (FN) during aplasia after haematopoietic stem cell transplantation (HSCT) in patients who received anti-bacterial prophylaxis with norfloxacin/ceftriaxone or ciprofloxacin, between September 2006 and May 2009. Methods: We retrospectively examined all patients undergoing HSCT at S?o Paulo Hospital during the study period. Results: Of the 107 studied patients, 71 (66.3%) were included in the analysis. The exclusion criteria were as follows: occurrence of fever or infection before the transplantation (17), prophylactic use of norfloxacin (6), fever of probable non-infectious aetiology (2), and absence of prophylaxis during the aplasia period (11). Thirty-eight patients received norfloxacin and ceftriaxone as prophylaxis (Group I) and 33 received ciprofloxacin (Group II). The groups were comparable with respect to age, underlying diseases, comorbidities, and status of the underlying disease. Patients in Group II used antibiotics in a significantly higher frequency than those in Group I (66.7% vs 33.8%, p = 0.017), for 30 days before transplantation. The number of previous hospitalisations, length of hospitalisation until transplantation, type of transplant, progenitor cells used, number of CD34 cells infused, type of conditioning, and graft-versus-host disease prophylaxis were similar in both groups. After the transplantation, 28.9% and 39.4% of the patients in Groups I and II, respectively, presented Grade III and IV mucositis (p = 0.448). Neutropenia of <500 neutrophils/mm3 lasted an average of 9.5 and 9.3 days in Groups I and II, whereas neutropenia of <100 neutrophils/mm3 lasted between 6.6 and 5.7 days. FN occurred in 78.9% of patients in Group I and 81.8% in Group II, with no significant difference in the classification of these episodes. Six patients (15.8%) in Group I and five (15.2%) in Group II had bacteraemia. All patients who did not receive prophylaxis developed FN. Conclusions: The high incidence and classification of FN episodes were similar between groups; however, the frequency was lower than in those patients who did not receive prophylaxis.

Share and Cite:

Fernandes, V. , Cappellano, P. , Bergamasco, M. , Goto, J. , Oliveira, J. and Pereira, C. (2014) Evaluation of Prophylaxis with Norfloxacin and Ceftriaxone versus Ciprofloxacin during the Period of Neutropenia after Haematopoietic Stem Cell Transplantation: Retrospective Analysis of Two Sequencial Cohorts. Advances in Infectious Diseases, 4, 77-86. doi: 10.4236/aid.2014.42013.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Tomblyn, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., Wingard, J.R., Young, J.A. and Boeckh, M.J. (2009) Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplant Recipients: A Global Perspective. Preface. Bone Marrow Transplant, 44, 453-455. http://dx.doi.orgdoi: /10.1038/bmt.2009.254
[2] Kruger, W., Russmann, B., Kroger, N., Salomon, C., Ekopf, N., Elsner, H.A., Kaulfers, P.M., Mack, D., Fuchs, N., Durken, M., Kabisch, H., Erttmann, R. and Zander, A.R. (1999) Early Infections in Patients Undergoing Bone Marrow or Blood Stem Cell Transplantation—A 7 Year Single Centre Investigation of 409 Cases. Bone Marrow Transplant, 23, 589-597. http://dx.doi.org/10.1038/sj.bmt.1701614
[3] Viscoli, C., Varnier, O. and Machetti, M. (2005) Infections in Patients with Febrile Neutropenia: Epidemiology, Microbiology, and Risk Stratification. Clinical Infectious Diseases, 40, S240-S245. http://dx.doi.org/10.1086/427329
[4] Collin, B.A., Leather, H.L., Wingard, J.R. and Ramphal, R. (2001) Evolution, Incidence, and Susceptibility of Bacterial Bloodstream Isolates from 519 Bone Marrow Transplant Patients. Clinical Infectious Diseases, 33, 947-953. http://dx.doi.org/10.1086/322604
[5] Mendes, E.T., Dulley, F., Basso, M., Batista, M.V., Coracin, F., Guimaraes, T., Shikanai-Yasuda, M.A., Levin, A.S. and Costa, S.F. (2012) Healthcare-Associated Infection in Hematopoietic Stem Cell Transplantation Patients: Risk Factors and Impact on Outcome. International Journal of Infectious Diseases, 16, E424-E428. http://dx.doi.org/10.1016/j.ijid.2012.01.015
[6] Oliveira, A.L., de Souza, M., Carvalho-Dias, V.M., Ruiz, M.A., Silla, L., Tanaka, P.Y., Simoes, B.P., Trabasso, P., Seber, A., Lotfi, C.J., Zanichelli, M.A., Araujo, V.R., Godoy, C., Maiolino, A., Urakawa, P., Cunha, C.A., de Souza, C.A., Pasquini, R. and Nucci, M. (2007) Epidemiology of Bacteremia and Factors Associated with Multi-Drug-Resistant Gram-Negative Bacteremia in Hematopoietic Stem Cell Transplant Recipients. Bone Marrow Transplant, 39, 775-781.
[7] Viscoli, C. (2007) Antibacterial Prophylaxis in Neutropenic Patients. International Journal of Antimicrobial Agents, 30, S60-S65. http://dx.doi.org/10.1016/j.ijantimicag.2007.06.016
[8] Flowers, C.R., Seidenfeld, J., Bow, E.J., Karten, C., Gleason, C., Hawley, D.K., Kuderer, N.M., Langston, A.A., Marr, K.A., Rolston, K.V. and Ramsey, S.D. (2013) Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 31, 794-810. http://dx.doi.org/10.1200/JCO.2012.45.8661
[9] Freifeld, A.G., Bow, E.J., Sepkowitz, K.A., Boeckh, M.J., Ito, J.I., Mullen, C.A., Raad, I.I., Rolston, K.V., Young, J.A. and Wingard, J.R. (2011) Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 52, E56-E93. http://dx.doi.org/10.1093/cid/cir073
[10] Tomblyn, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., Wingard, J.R., Young, J.A. and Boeckh, M.J. (2009) Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective. Biology of Blood and Marrow Transplantation, 15, 1143-1238. http://dx.doi.org/10.1016/j.bbmt.2009.06.019
[11] van de Wetering, M.D., de Witte, M.A., Kremer, L.C., Offringa, M., Scholten, R.J. and Caron, H.N. (2005) Efficacy of Oral Prophylactic Antibiotics in Neutropenic Afebrile Oncology Patients: A Systematic Review of Randomised Controlled Trials. European Journal of Cancer, 41, 1372-1382.
[12] Gafter-Gvili, A., Fraser, A., Paul, M. and Leibovici, L. (2005) Meta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients. Annals of Internal Medicine, 142, 979-995.
[13] Gafter-Gvili, A., Fraser, A., Paul, M., Vidal, L., Lawrie, T.A., van de Wetering, M.D., Kremer, L.C. and Leibovici, L. (2005) Antibiotic Prophylaxis for Bacterial Infections in Afebrile Neutropenic Patients Following Chemotherapy. The Cochrane Database of Systematic Reviews, Article ID: CD004386. http://dx.doi.org/10.1002/14651858.CD004386.pub3
[14] Bucaneve, G., Micozzi, A., Menichetti, F., Martino, P., Dionisi, M.S., Martinelli, G., Allione, B., D’Antonio, D., Buelli, M., Nosari, A.M., Cilloni, D., Zuffa, E., Cantaffa, R., Specchia, G., Amadori, S., Fabbiano, F., Deliliers, G.L., Lauria, F., Foa, R. and Del Favero, A. (2005) Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia. The New England Journal of Medicine, 353, 977-987. http://dx.doi.org/10.1056/NEJMoa044097
[15] Lew, M.A., Kehoe, K., Ritz, J., Antman, K.H., Nadler, L., Takvorian, T., Mayer, R., Kalish, L. and Finberg, R. (1991) Prophylaxis of Bacterial Infections with Ciprofloxacin in Patients Undergoing Bone Marrow Transplantation. Transplantation, 51, 630-636. http://dx.doi.org/10.1097/00007890-199103000-00017
[16] Perez-Simon, J.A., Garcia-Escobar, I., Martinez, J., Vazquez, L., Caballero, D., Canizo, C., Mateos, M.V. and San Miguel, J.F. (2004) Antibiotic Prophylaxis with Meropenem after Allogeneic Stem Cell Transplantation. Bone Marrow Transplantation, 33, 183-187.
[17] Eleutherakis-Papaiakovou, E., Kostis, E., Migkou, M., Christoulas, D., Terpos, E., Gavriatopoulou, M., Roussou, M., Bournakis, E., Kastritis, E., Efstathiou, E., Dimopoulos, M.A. and Papadimitriou, C.A. (2010) Prophylactic Antibiotics for the Prevention of Neutropenic Fever in Patients Undergoing Autologous Stem-Cell Transplantation: Results of a Single Institution, Randomized Phase 2 Trial. American Journal of Hematology, 85, 863-867. http://dx.doi.org/10.1002/ajh.21855
[18] Fernandez-Aviles, F., Carreras, E., Urbano-Ispizua, A., Rovira, M., Martinez, C., Gaya, A., Granell, M., Ramiro, L., Gallego, C., Hernando, A., Segura, S., Garcia, L., Gonzalez, M., Valverde, M. and Montserrat, E. (2006) Case-Control Comparison of At-Home to Total Hospital Care for Autologous Stem-Cell Transplantation for Hematologic Malignancies. Journal of Clinical Oncology, 24, 4855-4861. http://dx.doi.org/10.1200/JCO.2006.06.4238
[19] Solano, C., Gutierrez, A., Martinez, F., Gimeno, C., Gomez, C., Munoz, I., Faus, F., Goterris, R., Farga, A. and Navarro, D. (2005) Prophylaxis of Early Bacterial Infections after Autologous Peripheral Blood Stem Cell Transplantation (PBSCT): A Matched-Pair Study Comparing Oral Fluoroquinolones and Intravenous Piperacillin-Tazobactam. Bone Marrow Transplantation, 36, 59-65.
[20] Guthrie, K.A., Yong, M., Frieze, D., Corey, L. and Fredricks, D.N. (2010) The Impact of a Change in Antibacterial Prophylaxis from Ceftazidime to Levofloxacin in Allogeneic Hematopoietic Cell Transplantation. Bone Marrow Transplantation, 45, 675-681.
[21] Sohn, B.S., Yoon, D.H., Kim, S., Lee, K., Kang, E.H., Park, J.S., Lee, D.H., Kim, S.H., Huh, J. and Suh, C. (2012) The Role of Prophylactic Antimicrobials during Autologous Stem Cell Transplantation: A Single-Center Experience. European Journal of Clinical Microbiology & Infectious Diseases, 31, 1653-1661. http://dx.doi.org/10.1007/s10096-011-1489-2
[22] Vehreschild, J.J., Moritz, G., Vehreschild, M.J., Arenz, D., Mahne, M., Bredenfeld, H., Chemnitz, J., Klein, F., Cremer, B., Boll, B., Kaul, I., Wassmer, G., Hallek, M., Scheid, C. and Cornely, O.A. (2012) Efficacy and Safety of Moxifloxacin as Antibacterial Prophylaxis for Patients Receiving Autologous Haematopoietic Stem Cell Transplantation: A Randomised Trial. International Journal of Antimicrobial Agents, 39, 130-134. http://dx.doi.org/10.1016/j.ijantimicag.2011.10.009
[23] Urabe, A. (2004) Clinical Features of the Neutropenic Host: Definitions and Initial Evaluation. Clinical Infectious Diseases, 39, S53-S55. http://dx.doi.org/10.1086/383055
[24] Kiffer, C.R., Mendes, C., Oplustil, C.P. and Sampaio, J.L. (2007) Antibiotic Resistance and Trend of Urinary Pathogens in General Outpatients from a Major Urban City. International Braz J Urol: Official Journal of Brazilian Society of Urology (Int Braz J Urol), 33, 42-48. http://dx.doi.org/10.1590/S1677-55382007000100007
[25] Leibovici, L., Paul, M., Cullen, M., Bucaneve, G., Gafter-Gvili, A., Fraser, A. and Kern, W.V. (2006) Antibiotic Prophylaxis in Neutropenic Patients: New Evidence, Practical Decisions. Cancer, 107, 1743-1751. http://dx.doi.org/10.1002/cncr.22205
[26] Facchini, L., Martino, R., Ferrari, A., Pinana, J.L., Valcarcel, D., Barba, P., Granell, M., Delgado, J., Briones, J., Sureda, A., Brunet, S. and Sierra, J. (2012) Degree of Mucositis and Duration of Neutropenia Are the Major Risk Factors for Early Post-Transplant Febrile Neutropenia and Severe Bacterial Infections after Reduced-Intensity Conditioning. European Journal of Haematology, 88, 46-51. http://dx.doi.org/10.1111/j.1600-0609.2011.01724.x
[27] (1991) Prevention of Bacterial Infection in Neutropenic Patients with Hematologic Malignancies. A Randomized, Multicenter Trial Comparing Norfloxacin with Ciprofloxacin. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. Annals of Internal Medicine, 115, 7-12. http://dx.doi.org/10.7326/0003-4819-115-1-7

Copyright © 2021 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.